# Almonertinib as First-line Treatment in Patients With EGFR Mutations Positive in Advanced NSCLC With Brain Metastases

> **NCT04808752** · PHASE2 · UNKNOWN · sponsor: **Zhejiang Cancer Hospital** · enrollment: 63 (estimated)

## Conditions studied

- Lung Cancer

## Interventions

- **DRUG:** Almonertinib

## Key facts

- **NCT ID:** NCT04808752
- **Lead sponsor:** Zhejiang Cancer Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2021-07-09
- **Primary completion:** 2024-06-15
- **Final completion:** 2024-07-15
- **Target enrollment:** 63 (ESTIMATED)
- **Last updated:** 2024-04-22

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04808752

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04808752, "Almonertinib as First-line Treatment in Patients With EGFR Mutations Positive in Advanced NSCLC With Brain Metastases". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT04808752. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*